Shandong Jincheng Pharmaceutical Group Co.,Ltd. Drug Registration Certificate for Adenosyl Methionine Butanesulfonate Enteric-Coated Tablets Approved
Shandong Jincheng Pharmaceutical Group Co.,Ltd. Drug Registration Certificate for Adenosyl Methionine Butanesulfonate Enteric-Coated Tablets Approved
On October 20, Beijing Jincheng Taier Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Shandong Jincheng Pharmaceutical Group Co., Ltd., received the drug registration certificate for adenosylmethionine enteric-coated tablets issued by the State Food and Drug Administration.
Adenosylmethionine butisulfonate enteric-coated tablets are an important drug for the treatment of liver diseases and are widely used for the treatment of intrahepatic cholestasis before and due to cirrhosis, as well as for the adjuvant treatment of intrahepatic cholestasis during pregnancy. By providing exogenous adenosylmethionine, this drug promotes phospholipid methylation of liver cell membranes, enhances liver detoxification function, and improves bile metabolism. It plays an important role in the clinical treatment of hepatobiliary diseases. In my country, with the increasing clinical demand for liver and gallbladder health management, the market size of adenosylmethionine enteric-coated tablets is expanding year by year. According to statistics from Minai.com, sales of adenosylmethionine enteric-coated tablets in domestic public medical institutions from 2022 to 2024 were 428 million yuan, 403 million yuan, and 460 million yuan respectively. Sales showed a steady growth trend, showing good market prospects and clinical recognition.
The approval of adenosylmethionine butanedisulfonate enteric-coated tablets realizes the company's entire industrial chain layout from raw materials to pharmaceutical preparations for this variety. It is an important achievement achieved by the company's unified R&D management and the deepening of industrial chain collaboration for integrated pharmaceuticals and synthetic biological high-quality raw materials. The company now has two dosage forms of adenosylmethionine butanedisulfonate, oral and injectable, providing more options for the clinical treatment of intrahepatic cholestasis, and will further enrich the company's digestive system and liver disease product lines and enhance the company's comprehensive market competitiveness and brand influence in related treatment fields.
In the future, the company will continue to focus on clinical needs, strictly control product quality, accelerate the production and marketing of this drug, benefit the majority of patients, and contribute more Jincheng good medicines to the treatment of hepatobiliary diseases in my country.
(Contributed by the Institute and Thiel)